Skip to content

Functional Outcomes and QoL in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by RARP

Intermediate Term Functional Outcomes and Quality of Life in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by Robot-assisted Laparoscopic Prostatectomy (RALP)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03790995
Enrollment
9235
Registered
2019-01-02
Start date
2009-10-31
Completion date
2018-02-28
Last updated
2019-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Function, Prostate Cancer, Quality of Life, Urinary Function

Keywords

Prostate cancer, Robot assisted radical prostatectomy, RALP, RARP, High risk, Intermediate risk, Low risk, Urinary, Erectile, Quality of life, QoL, Post operation, functional outcomes, follow-up

Brief summary

The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This database investigates the status after robot assisted laparoscopic prostatectomy (RALP) in prostate cancer patients. It was established by a collaboration between the Belgian association of Urology (BAU), the National Institute for Health and Disability Insurance (NIHDI) and the Belgian cancer registry. Between 2009 and 2016, 9235 patients were included in this patient registry. The studied outcomes covered quality of life measures as well as variables covering urinary and erectile function.

Detailed description

The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This was established by a collaboration between the Belgian association of Urology (BAU), the National Institute for Health and Disability Insurance (NIHDI) and the Belgian cancer registry. Twenty-five centres, on average 90% of all Belgian robotic centres, collected prospective data of 9235 patients from October 2009 until February 2016. These data is collected by local data managers or physicians and was required to receive reimbursion from the NIHDI for the disposables used during robot surgery. After filling in the data by the local datamanagers, the data is centralised. In Brussels the data is protected and further used by data managers and statisticians. In this system in-and output of data is strictly separated. Patient data is encoded to ensure absolute privacy. Then the data is checked upon correctness by using random checks. Data is completed where necessary. These parameters increase the quality of data handling and database. The final database consists of baseline pre-, per- and postoperative data as well as four standardised follow-up registrations (on 1, 3, 12 and 24 months), with follow-up data still being collected. In each follow-up registration, functional parameters and quality of life are re-assessed together with postoperative treatment status and PSA. The Be-RALP database collected patient details of 9235 patients treated by RARP between 2009 and 2016. Patients with macro metastasis and initial PSA values higher than 100 (probable undetected micro metastasis) were excluded for this study, as well as all pT0, patients with surgery after the closing date and patients with invalid survival data. Further exclusion of patients with missing values for nerve sparing, extend of nerve sparing and risk category resulted in a group of 8306 patients. The selected outcomes covered in the database consist of quality of life measures (European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 global, physical, emotional and cognitive) as well as variables covering urinary (Incontinence Modular Questionnaire-Urinary Incontinence: ICIQ, EORTC QLQ-PR25 urinary symptoms, incontinence aid) and erectile function (International Index of Erectile Function: IIEF, EORTC QLQ-PR25 sexual activity and sexual functioning). A 1:1 matching between high and low-intermediate prostate cancer will be performed. Afterwards, longitudinal mixed models will quantify the relation between the explanatory variables follow-up time, risk group (high vs. low-intermediate) and postoperative treatment (postoperative radiotherapy (RT) and/or androgen deprivation therapy (ADT): yes vs. no) and the outcomes erectile- and urinary function as well as Quality of Life. All analysis will be performed using the statistical analysis software (SAS system), version 9.3.

Interventions

Sponsors

Belgian Cancer Registry
CollaboratorOTHER
KU Leuven
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

* Diagnosed with prostate cancer * Eligible to undergo RALP * RALP in one of the 25 participating centres

Exclusion criteria

* iPSA \> 100 * Confirmed metastasis * invalid survival data * pT0 * Missing nerve sparing details * Missing risk group

Design outcomes

Primary

MeasureTime frameDescription
Global quality of lifeLongitudinal modelling over 24 monthsEORTC C30 global quality of life, questionnaire
Emotional quality of lifeLongitudinal modelling over 24 monthsEORTC C30 emotional quality of life, questionnaire
physical quality of lifeLongitudinal modelling over 24 monthsEORTC C30 physical quality of life, questionnaire
Cognitive quality of lifeLongitudinal modelling over 24 monthsEORTC C30 cognitive quality of life, questionnaire
Erectile function - IIEF 5Longitudinal modelling over 24 monthsInternational Index of Erectile Function (IIEF-5), questionnaire
Erectile function - sexual activityLongitudinal modelling over 24 monthsEORTC PR25 sexual activity, questionnaire
Erectile function - sexual functioningLongitudinal modelling over 24 monthsEORTC PR25 sexual functioning, questionnaire
Urinary function - Incontinence aidLongitudinal modelling over 24 monthsEORTC PR25 incontinence aid, questionnaire
Urinary function - urinary symptomsLongitudinal modelling over 24 monthsEORTC PR25 urinary symptoms, questionnaire
Urinary function - ICIQLongitudinal modelling over 24 monthsInternational Consultation on Incontinence Questionnaire

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026